Sarepta Therapeutics (AB3A) Stock Forecast & Price Target

5 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AB3A Analyst Ratings

Hold

5 Buy

7 Hold

4 Sell

Based on 16 analysts giving stock ratings to

Sarepta

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AB3A Stock 12 Month Forecast

Average Price Target

€19.92

▲(44.76% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is €19.92 with a high forecast of €33.01 and a low forecast of €4.34. The average price target represents a 44.76% change from the last price of €13.76.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"€3","34":"€34","10.75":"€10.75","18.5":"€18.5","26.25":"€26.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":33.006396439999996,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€33.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.919649781333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€19.92</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.342946899999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€4.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,10.75,18.5,26.25,34],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13,14.538953572307692,16.077907144615384,17.616860716923075,19.15581428923077,20.69476786153846,22.23372143384615,23.772675006153843,25.311628578461537,26.850582150769227,28.389535723076918,29.928489295384612,31.467442867692302,{"y":33.006396439999996,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13,13.532280752410257,14.064561504820514,14.596842257230769,15.129123009641026,15.661403762051282,16.193684514461538,16.725965266871796,17.25824601928205,17.790526771692306,18.322807524102565,18.85508827651282,19.387369028923075,{"y":19.919649781333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,13,12.33407283846154,11.668145676923077,11.002218515384616,10.336291353846153,9.670364192307693,9.004437030769232,8.33850986923077,7.672582707692308,7.006655546153846,6.340728384615384,5.674801223076923,5.008874061538462,{"y":4.342946899999999,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.9,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 81, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 27</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.34,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 69, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 26</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.285,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 34, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":20.01,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.335,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.405,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.81,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.63,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.54,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.84,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€33.01

Average Price Target€19.92

Lowest Price Target€4.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

€4.34

Sell

-68.44%

Downside

Reiterated

07/28/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (NASDAQ: VCEL), Sarepta Therapeutics (NASDAQ: SRPT) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Michael Ulz

Morgan Stanley

€21.71

Hold

57.81%

Upside

Reiterated

07/27/26

Morgan Stanley says Sarepta's CEO transition brings clarity ahead of catalystsMorgan Stanley says Sarepta's CEO transition brings clarity ahead of catalysts

Yigal Nochomovitz

Citi

€11.29

Sell

-17.94%

Downside

Reiterated

07/20/26

Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13

Tazeen Ahmad

Bank of America Securities

€16.5

Sell

19.94%

Upside

Reiterated

07/15/26

Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)

Uy Ear

Mizuho Securities

€26.93

Buy

95.69%

Upside

Reiterated

07/10/26

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX), Sarepta Therapeutics (NASDAQ: SRPT) and Opus Genetics (NASDAQ: IRD)

Biren Amin

Piper Sandler

€17.37

Hold

26.25%

Upside

Assigned

07/09/26

Sarepta price target lowered to $20 from $23 at Piper SandlerSarepta price target lowered to $20 from $23 at Piper Sandler

Andy Chen

Wolfe Research

€23.45

Buy

70.44%

Upside

Upgraded

07/08/26

Sarepta upgraded to Outperform from Peer Perform at Wolfe ResearchSarepta upgraded to Outperform from Peer Perform at Wolfe Research

Brian Abrahams

RBC Capital

€16.5

Hold

19.94%

Upside

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)

Yun Zhong

Wedbush

€30.4

Buy

120.93%

Upside

Reiterated

06/30/26

Analysts' Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)

Eliana Merle

Barclays

€17.37

Hold

26.25%

Upside

Reiterated

06/22/26

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Eli Lilly & Co (NYSE: LLY) and C4 Therapeutics (NASDAQ: CCCC)

Anupam Rama

J.P. Morgan

€15.63→€16.5

Hold

19.94%

Upside

Reiterated

05/18/26

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

Gavin Clark-Gartner

Evercore ISI

€17.37→€16.5

Hold

19.94%

Upside

Reiterated

05/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (NYSE: ZTS), Sarepta Therapeutics (NASDAQ: SRPT) and GoodRx Holdings (NASDAQ: GDRX)

Ritu Baral

TD Cowen

€14.77

Hold

7.31%

Upside

Reiterated

05/07/26

Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward

Gil Blum

Needham

―

Sell

―

Reiterated

05/07/26

Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount

Yanan Zhu

Wells Fargo

€33.01

Buy

139.87%

Upside

Reiterated

05/07/26

Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

€4.34

Sell

-68.44%

Downside

Reiterated

07/28/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (NASDAQ: VCEL), Sarepta Therapeutics (NASDAQ: SRPT) and Neumora Therapeutics, Inc. (NASDAQ: NMRA)

Michael Ulz

Morgan Stanley

€21.71

Hold

57.81%

Upside

Reiterated

07/27/26

Morgan Stanley says Sarepta's CEO transition brings clarity ahead of catalystsMorgan Stanley says Sarepta's CEO transition brings clarity ahead of catalysts

Yigal Nochomovitz

Citi

€11.29

Sell

-17.94%

Downside

Reiterated

07/20/26

Sell Rating Reiterated on Sarepta as Dyne’s z-rostudirsen Heightens Franchise Risk; Price Target Maintained at $13

Tazeen Ahmad

Bank of America Securities

€16.5

Sell

19.94%

Upside

Reiterated

07/15/26

Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)

Uy Ear

Mizuho Securities

€26.93

Buy

95.69%

Upside

Reiterated

07/10/26

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (NASDAQ: FBRX), Sarepta Therapeutics (NASDAQ: SRPT) and Opus Genetics (NASDAQ: IRD)

Biren Amin

Piper Sandler

€17.37

Hold

26.25%

Upside

Assigned

07/09/26

Sarepta price target lowered to $20 from $23 at Piper SandlerSarepta price target lowered to $20 from $23 at Piper Sandler

Andy Chen

Wolfe Research

€23.45

Buy

70.44%

Upside

Upgraded

07/08/26

Sarepta upgraded to Outperform from Peer Perform at Wolfe ResearchSarepta upgraded to Outperform from Peer Perform at Wolfe Research

Brian Abrahams

RBC Capital

€16.5

Hold

19.94%

Upside

Reiterated

07/07/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Healthequity (NASDAQ: HQY), Sarepta Therapeutics (NASDAQ: SRPT) and COMPASS Pathways (NASDAQ: CMPS)

Yun Zhong

Wedbush

€30.4

Buy

120.93%

Upside

Reiterated

06/30/26

Analysts' Top Healthcare Picks: Palisade Bio (PALI), Sarepta Therapeutics (SRPT)

Eliana Merle

Barclays

€17.37

Hold

26.25%

Upside

Reiterated

06/22/26

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Eli Lilly & Co (NYSE: LLY) and C4 Therapeutics (NASDAQ: CCCC)

Anupam Rama

J.P. Morgan

€15.63→€16.5

Hold

19.94%

Upside

Reiterated

05/18/26

J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)

Gavin Clark-Gartner

Evercore ISI

€17.37→€16.5

Hold

19.94%

Upside

Reiterated

05/15/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (NYSE: ZTS), Sarepta Therapeutics (NASDAQ: SRPT) and GoodRx Holdings (NASDAQ: GDRX)

Ritu Baral

TD Cowen

€14.77

Hold

7.31%

Upside

Reiterated

05/07/26

Ritu Baral Reiterates Hold on Sarepta, Maintains $17 Price Target Amid Mixed Operating Profile and Balanced Risk-Reward

Gil Blum

Needham

―

Sell

―

Reiterated

05/07/26

Gil Blum Reiterates Sell on Sarepta as Elevidys Momentum Slows and Regulatory Risks Mount

Yanan Zhu

Wells Fargo

€33.01

Buy

139.87%

Upside

Reiterated

05/07/26

Wells Fargo Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

ZURAZura Bio

TNYATenaya Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sarepta Therapeutics

3 Months

Debjit ChattopadhyayGuggenheim

Success Rate

20/35 ratings generated profit

Average Return

+8.13%

Copying Debjit Chattopadhyay's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +8.13% per trade.

1 Year

Yun ZhongWedbush

Success Rate

13/24 ratings generated profit

Average Return

+7.79%

Copying Yun Zhong's trades and holding each position for 1 Year would result in 54.17% of your transactions generating a profit, with an average return of +7.79% per trade.

2 Years

Gil BlumNeedham

Success Rate

13/31 ratings generated profit

Average Return

-29.44%

Copying Gil Blum's trades and holding each position for 2 Years would result in 41.94% of your transactions generating a profit, with an average return of -29.44% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AB3A Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AB3A has received 3 Buy Ratings, 6 Hold Ratings, and 4 Sell Ratings. AB3A average Analyst price target in the past 3 months is 19.92.

Each month's total comprises the sum of three months' worth of ratings.

AB3A Financial Forecast

AB3A Earnings Forecast

Next quarter’s earnings estimate for AB3A is €0.19 with a range of -€0.41 to €0.67. The previous quarter’s EPS was -€0.04. AB3A beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.99% of the time in the same period. In the last calendar year AB3A has Performed in-line its overall industry.

AB3A Sales Forecast

Next quarter’s sales forecast for AB3A is €321.03M with a range of €275.71M to €392.04M. The previous quarter’s sales results were €348.02M. AB3A beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.69% of the time in the same period. In the last calendar year AB3A has Performed in-line its overall industry.

AB3A Stock Forecast FAQ

What is DE:AB3A’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is 19.92.

What is DE:AB3A’s upside potential, based on the analysts’ average price target?

Sarepta Therapeutics has 44.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sarepta Therapeutics a Buy, Sell or Hold?

Sarepta Therapeutics has a consensus rating of Hold, which is based on 5 buy ratings, 7 hold ratings and 4 sell ratings.

What is Sarepta Therapeutics’s share price target?

The average share price target for Sarepta Therapeutics is 19.92. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €33.01 ,and the lowest forecast is €4.34. The average share price target represents 44.76% Increase from the current price of €13.76.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Sarepta Therapeutics?

To buy shares of DE:AB3A, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sarepta Therapeutics (AB3A) Stock Forecast & Price Target

AB3A Analyst Ratings

AB3A Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

AB3A Analyst Recommendation Trends

AB3A Financial Forecast

AB3A Earnings Forecast

AB3A Sales Forecast

AB3A Stock Forecast FAQ

Detailed List of Analyst Forecasts